Acadia Pharmaceuticals Reports P-III (ADVANCE-2) Study Results of Pimavanserin to Treat Negative Schizophrenia Symptoms
Shots:
- Acadia Pharmaceuticals has reported top-line data from the P-III (ADVANCE-2) study of pimavanserin for treating negative schizophrenia symptoms
- The 26 wks. P-III (ADVANCE-2) study assessed pimavanserin (34mg) vs PBO for the treatment of adults (n=454) with negative schizophrenia symptoms who controlled their positive symptoms with antipsychotic treatment
- The study did not show improvement in the 1EP demonstrating a change in the NSA-16 total score of -11.8 vs -11.1 from baseline to wk. 26 which was similar to that observed in the ADVANCE-1 study (-11.8 vs -11.6). Additionally, the PBO effect was -11.1 & -8.5 in ADVANCE-2 & ADVANCE-1 studies, respectively
Ref: Acadia | Image: Acadia
Related News:- Acadia Expands its License Agreement with Neuren to Acquire Ex-North American Rights to Trofinetide and Global Rights to NNZ-2591
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
